Claims for Patent: 12,109,178

Summary for Patent: 12,109,178

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US17/821,342
Patent Claims:	1. A method of treating major depressive disorder, comprising orally administering a dosage form once a day or twice a day to a human patient in need thereof, wherein the dosage form contains about 40 mg to about 50 mg of a dextromethorphan salt, or a molar equivalent amount of the free base form of dextromethorphan, and about 100 mg to about 110 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form or the free base form of bupropion. 2. The method of claim 1, wherein the dosage form contains about 45 mg of the dextromethorphan salt. 3. The method of claim 1, wherein the dosage form is orally administered once a day for three days, and after three days, the dosage form is orally administered twice a day. 4. The method of claim 1, wherein the dosage form contains about 105 mg of bupropion hydrochloride. 5. The method of claim 4, wherein the dosage form contains about 45 mg of the dextromethorphan salt. 6. The method of claim 5, wherein the dosage form is orally administered once a day for three days, and after three days, the dosage form is orally administered twice a day. 7. The method of claim 6, wherein the dosage form provides sustained release of bupropion and immediate release of dextromethorphan. 8. The method of claim 7, wherein the dosage form is in the form of a tablet. 9. The method of claim 8, wherein the tablet further contains magnesium stearate. 10. The method of claim 9, wherein the tablet further contains microcrystalline cellulose. 11. The method of claim 1, wherein the dextromethorphan salt is dextromethorphan hydrobromide. 12. The method of claim 11, wherein the dosage form contains about 45 mg of dextromethorphan hydrobromide. 13. The method of claim 12, wherein the dosage form contains about 105 mg of bupropion hydrochloride. 14. The method of claim 13, wherein the dosage form is orally administered once a day for three days, and after three days, the dosage form is orally administered twice a day. 15. The method of claim 14, wherein the dosage form provides sustained release of bupropion and immediate release of dextromethorphan. 16. The method of claim 15, wherein the dosage form is in the form of a tablet. 17. The method of claim 16, wherein the tablet further contains magnesium stearate. 18. The method of claim 17, wherein the tablet further contains microcrystalline cellulose.